Core Viewpoint - The retail pharmacy sector experienced a significant rise in stock prices following the release of a government policy aimed at promoting high-quality development in the pharmaceutical retail industry [1] Group 1: Policy Impact - On January 22, the Ministry of Commerce and nine other departments issued guidelines to encourage horizontal mergers and acquisitions in the pharmaceutical retail sector [1] - The policy aims to optimize the business environment for retail pharmacies, including streamlining the application process for drug operating licenses for consolidated chain or standalone pharmacies [1] - It promotes the integration of wholesale and retail operations to enhance supply chain efficiency and reduce operational costs through shared logistics resources and collaborative quality management systems [1] Group 2: Market Outlook - According to Guojin Securities, leading compliant pharmacy chains are expected to benefit first from the ongoing regulatory push for industry standardization [1] - Companies that have proactively adjusted their store operations are projected to see a marginal recovery in revenue by the third quarter of 2025 [1] - Some leading companies are beginning to explore non-pharmaceutical product offerings, which could become a significant source of profit if they exceed expectations in performance [1]

Core Viewpoint - Yifeng Pharmacy (SH603939) reached its daily limit with a price of 24.81 yuan, marking a 10.02% increase and a total market capitalization of 30.079 billion yuan, driven by performance growth, regional expansion, and standardized governance [1] Group 1: Performance Growth - In Q3 2025, Yifeng Pharmacy reported a net profit increase of 10.27% year-on-year, with franchise business revenue growing by 17.45% [1] - Revenue from the North China region increased by 4.01%, indicating effective regional strategy implementation [1] Group 2: Governance and Incentives - The company has a well-regulated governance structure, strictly adhering to its equity incentive plan, with guarantees and financial management within authorized limits [1] - The net profit for 2024 is projected to grow by 71.98% compared to the benchmark, exceeding assessment targets [1] Group 3: Market Dynamics - On the day of the stock surge, the overall capital flow in the pharmaceutical commercial sector was positive, attracting funds to Yifeng Pharmacy as a well-known entity in the industry [1] - Technically, the stock's MACD indicator had formed a golden cross, indicating enhanced short-term upward momentum [1]

Industry Overview - The Ministry of Commerce and nine other departments issued opinions on promoting high-quality development in the retail pharmaceutical industry, supporting mergers and acquisitions among retail pharmacies [1] - The retail pharmacy sector is expected to accelerate its consolidation by 2025, with customer traffic likely concentrating towards leading players [1] - As of the end of Q3 2025, the total number of pharmacies in China is projected to be 686,426, reflecting a net decrease of nearly 20,000 stores since Q4 2024 [1] - The number of pharmacies has shown negative growth for four consecutive quarters, indicating a rapid contraction in the industry [1] Company Insights - Lao Bai Xing is recognized as one of the leading retail pharmacy chains in China, primarily engaged in the sale of pharmaceuticals and health-related products through its marketing network [1] - Yifeng Pharmacy focuses on the retail of pharmaceuticals, health products, medical devices, and daily convenience items related to health [1]

Core Viewpoint - Yifeng Pharmacy's stock price has experienced fluctuations, with a recent decline of 2.08% and a total market capitalization of 26.77 billion yuan. The company has shown a modest year-to-date increase of 1.66% in stock price, but has faced declines over various trading periods [1]. Financial Performance - For the period from January to September 2025, Yifeng Pharmacy achieved a revenue of 17.286 billion yuan, reflecting a year-on-year growth of 0.39%. The net profit attributable to shareholders was 1.225 billion yuan, marking a growth of 10.27% compared to the previous year [2]. - Cumulatively, since its A-share listing, Yifeng Pharmacy has distributed a total of 2.852 billion yuan in dividends, with 1.946 billion yuan distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Yifeng Pharmacy was 20,200, a decrease of 6.41% from the previous period. The average circulating shares per person increased by 6.85% to 59,920 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 199 million shares, a decrease of 38.1935 million shares from the previous period. New shareholder,交银新成长混合, holds 8.4541 million shares, while 中欧医疗健康混合A has exited the top ten list [3]. Business Overview - Yifeng Pharmacy, established on June 20, 2008, and listed on February 17, 2015, operates in the retail of pharmaceuticals, health products, medical devices, and related daily convenience items. The revenue composition includes 78.11% from Western and Chinese medicines, 12.16% from non-pharmaceuticals, and 9.72% from traditional Chinese medicines [1]. - The company is categorized under the pharmaceutical and biological industry, specifically in the offline pharmacy segment, and is associated with concepts such as pharmaceutical e-commerce and retail pharmacies [1].

Core Viewpoint - The pharmaceutical commercial sector experienced a slight increase of 0.39% on January 19, with significant contributions from stocks like Dajia Weikang, which led the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4114.0, up by 0.29%, while the Shenzhen Component Index closed at 14294.05, up by 0.09% [1] - Dajia Weikang (301126) led the sector with a closing price of 13.91, reflecting a rise of 6.43% and a trading volume of 162,500 shares, amounting to a transaction value of 220 million yuan [1] - Other notable performers included Dacianlin (603233) with a 4.37% increase, Guofang Co. (600538) up by 3.27%, and Yifeng Pharmacy (603939) rising by 2.55% [1] Group 2: Fund Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 436 million yuan from institutional investors, while retail investors contributed a net inflow of 486 million yuan [2] - The individual stock fund flow indicated that Ruikang Pharmaceutical (002589) had a net inflow of 19.77 million yuan from institutional investors, while it faced a net outflow of 17.52 million yuan from retail investors [3] - Dajia Weikang (301126) also experienced a net inflow of 13.40 million yuan from institutional investors, despite a net outflow of 15.06 million yuan from retail investors [3]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 19, 2026 [1] Core Insights - 2025 marked a significant year for Chinese innovative drugs going global, with a total transaction amount of $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs. The trend continues into 2026, with notable licensing agreements from companies like Yilian Biotech and Rongchang Biotech, indicating strong global competitiveness for Chinese innovative drugs [2] - Major companies are increasingly investing in the small nucleic acid field, with significant acquisitions and clinical approvals. For instance, China National Pharmaceutical Group acquired Hangzhou Hejiya Biopharmaceutical for 1.2 billion RMB, while international firms like Novartis and GSK are also advancing in this area [3] - The GLP-1 market is expected to grow despite new pricing systems, with ongoing collaborations and new product launches anticipated in 2026. The market for GLP-1 drugs is projected to remain robust due to the large patient population for weight loss and diabetes [4] - The oral autoimmune drug market is gaining attention, with promising results from Takeda's new TYK2 inhibitor for psoriasis. Other domestic companies are also advancing in this space, exploring new targets for oral small molecules [5] - The brain-computer interface sector is poised for industrialization, with companies like Neuralink set to produce devices in 2026. Domestic advancements and regulatory support are enhancing the potential for this technology in medical applications [6] - The ZAP-X radiation therapy device is expected to capture a significant market share in China, with rapid growth projected in non-invasive tumor radiation treatment, driven by increasing clinical recognition and adoption [8] Summary by Sections Industry Trends - The pharmaceutical sector is witnessing a resurgence in interest towards innovative drugs, with a notable increase in the innovative drug index by 8.97% since early January 2026, outperforming the CSI 300 index by 6.77 percentage points [2] Company Recommendations - Recommended companies include: - **Yuekang Pharmaceutical** and **Sunshine Nuohua** in the small nucleic acid space - **Yahong Pharmaceutical** and **Yifang Biotechnology** in the autoimmune sector - **Zhongsheng Pharmaceutical** in the GLP-1 market - **Baiyang Pharmaceutical** for ZAP-X radiation therapy - **Meihao Medical** for brain-computer interface technology [10] Market Opportunities - The non-invasive tumor radiation treatment market is projected to grow from 27.2 billion RMB in 2018 to 59.4 billion RMB by 2024, with a compound annual growth rate of 13.9% [8]

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]

Core Viewpoint - Yifeng Pharmacy (603939) announced an increase in guarantees for its subsidiary Shijiazhuang Xinxing by 585 million yuan, raising the total guarantee balance to 950 million yuan, with no overdue guarantees reported [1] Summary by Relevant Categories Company Guarantees - The company has provided additional guarantees amounting to 585 million yuan for its subsidiary, bringing the cumulative guarantee balance to 950 million yuan [1] - The total external guarantees provided by the company and its subsidiaries amount to 2.56 billion yuan, which represents 23.87% of the most recent audited net assets [1]

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2026-002 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象 被担保人名称 石家庄新兴药房连锁有限公司（以下简 称"石家庄新兴"） 本次担保金额 58,500.00 万元 实际为其提供的担保余额 95,000.00 万元 是否在前期预计额度内 ☑是 □否 □不适用：_________ 本次担保是否有反担保 □是 ☑否 □不适用：_________ （二）内部决策程序 公司于 2025 年 4 月 28 日召开的第五届董事会第十六次会议与 2025 年 5 月 29 日召开的 2024 年年度股东会，审议通过了《关于为子公司申请银行授信提供 担保的议案》，石家庄新兴因经营发展需要，向银行申请授信额度，公司对其授 信进行担保，担保总额合计不超过 194,500.00 万元 ...

Market Performance - The pharmaceutical commercial sector increased by 0.97% compared to the previous trading day, with Luyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Key stocks in the pharmaceutical commercial sector showed significant gains, with Yinghe Pharmaceutical rising by 10.02% to a closing price of 22.72, and Jiashitang also increasing by 10.00% to 17.38 [1] - Other notable performers included Saili Medical and Renmin Tongtai, both showing increases of 10.00% and 2.64% respectively [1] Trading Volume and Value - Yinghe Pharmaceutical had a trading volume of 636,200 shares, resulting in a transaction value of approximately 1.396 billion yuan [1] - Jiashitang and Saili Medical also reported substantial trading volumes of 119,600 and 74,200 shares, with transaction values of around 208 million yuan and 185 million yuan respectively [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 188 million yuan from institutional investors and 252 million yuan from speculative funds, while retail investors saw a net inflow of 439 million yuan [2] - The capital flow data indicates varying investor sentiment, with retail investors showing a positive trend in the sector [2] Stock-Specific Capital Flow - Luyuan Pharmaceutical had a net inflow from retail investors of approximately 1.02 billion yuan, despite a net outflow from institutional and speculative investors [3] - Jiashitang and Saili Medical also experienced mixed capital flows, with Jiashitang seeing a net inflow of 84.96 million yuan from institutional investors [3]